Denis Chem Lab Ltd (DENISCHEM) — shareholding pattern, promoter holding, financials and share price
About Denis Chem Lab Ltd (DENISCHEM)
Denis Chem Lab Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as DENISCHEM and on the BSE under scrip code 537536. Its ISIN is INE051G01012.
Incorporated in 1982, Denis Chem Lab Ltd does manufacturing of Pharmaceuticals Transfusion Solution in Bottles [1]
Denis Chem Lab Ltd is a pharmaceutical company primarily focused on manufacturing sterile intravenous (IV) injectables and transfusion solutions.
The company leverages advanced Blow Fill Seal (BFS) technology to produce IV fluids in plastic bottles, reaching a capacity of 15 million units per annum by 2016.
Listed peers in Pharmaceuticals: Krebs Biochemicals & Industries Ltd, Sotac Pharmaceuticals Ltd, Par Drugs & Chemicals Ltd, Vaishali Pharma Ltd, Mercury Laboratories Ltd, Concord Drugs Ltd.
Valuation & Returns
10 Jul 2026At ₹76.22 a share on 10 Jul 2026, Denis Chem Lab Ltd (DENISCHEM) was valued at a price-to-earnings ratio of 12.58x against an industry P/E of 36.41x and a price-to-book of 1.24x on a book value of ₹61.33 per share as of Mar 2025. Solomo computes return on equity of 9.88% and return on capital employed of 14.83% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 12.58x
- Industry P/E
- 36.41x
- P/B
- 1.24x
- EPS (TTM)
- ₹6.06
- Book value / share
- ₹61.33
- ROE
- 9.88%
- ROCE
- 14.83%
- ROA
- 7.49%
- Debt / equity
- 0.01x
- Dividend yield
- 1.97%
- EBITDA margin
- 11.85%
- 52-week range
- ₹56.1 – ₹104.75
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Denis Chem Lab Ltd (DENISCHEM) reported revenue of ₹182 crore, net profit of ₹8 crore and earnings per share of ₹6.06. That compares with revenue of ₹173 crore and net profit of ₹8 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹46.75 crore and net profit ₹0.4 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 136 | 161 | 167 | 173 | 182 |
| Net profit (₹ cr) | 6 | 8 | 11 | 8 | 8 |
| EPS (₹) | 4.51 | 5.66 | 8.04 | 5.82 | 6.06 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.85% | 4.94% | 8.27% | 3.27% |
| Profit growth | - | 13.89% | 8.84% | -27.60% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 38.98% of Denis Chem Lab Ltd (DENISCHEM) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.01%. Market capitalisation was ₹106 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2013.
Largest disclosed public shareholders in Jun 2026: V-S Holding B.V. 20.74%, Own Infracon Private Limited 8.63%, Kanchan Pramodkumar Daga 5.78%, Varun Daga 1.7%, Shreans Daga 1.66%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 38.98% | - | 0.01% | - | 61.02% |
| Mar 2026 | 38.98% | - | 0.01% | - | 61.02% |
| Dec 2025 | 38.98% | - | 0.01% | - | 61.02% |
| Sep 2025 | 38.98% | - | 0.01% | - | 61.02% |
| Jun 2025 | 38.98% | - | 0.01% | - | 61.02% |
| Mar 2025 | 38.98% | - | - | - | 61.02% |
| Dec 2024 | 38.98% | - | - | - | 61.02% |
| Sep 2024 | 38.98% | - | - | - | 61.02% |